| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-11-10 | Genentech, a member of Roche Group (USA - CA - Switzerland) Halozyme Therapeutics (USA - CA) | PEGPH20 and Tecentriq® (atezolizumab) | eight undisclosed different tumor types | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-11-10 | Genexine (Republic of Korea) Merck&Co (USA - NJ) | GX-188E and Keytruda® (pembrolizumab) | HPV-induced cancers | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-11-10 | BMS (USA - NY) Nitto Denko (Japan) | siRNA molecules targeting heat shock protein 47 (HSP47) in vitamin A containing formulations including ND-L02-s0201 | NASH (non-alcoholic steatohepatitis), lung fibrosis and other organ fibrosis | licensing development commercialisation |
Liver diseases - Hepatic diseases - Fibrotic diseases | Licensing agreement |
| 2016-11-10 | Heptares Therapeutics (UK) Jitsubo (Japan), wholly-owned subsidiaries of Sosei Group (Japan) | peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastro-intestinal disorders | development collaboration |
Gastrointestinal diseases - Digestive diseases | Development agreement | |
| 2016-11-10 | Wave LIfe Sciences (USA - MA) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2016-11-09 | BMS (USA - NY) Infinity Pharmaceuticals (USA - MA) | Opdivo® (nivolumab) in combination with IPI-549 | solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-11-09 | Takeda Pharmaceutical (Japan) Center for iPS Cell Research and Application, Kyoto University (Japan) Yokohama City University (Japan) | miniature livers from human iPS cells for drug discovery | R&D | Technology - Services | R&D agreement | |
| 2016-11-09 | Avrobio (USA - MA) | nomination | Cancer - Oncology - Rare diseases - Genetic diseases | Nomination | ||
| 2016-11-08 | Mylan (USA - PA) Mabion (Poland) | Mabion CD20 (biosimilar version of Mabthera®/Rituxan® - rituximab) | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2016-11-08 | Neurovive Pharmaceutical (Sweden) | nomination | Rare diseases - Genetic diseases - Neurological diseases - Metabolic diseases | Nomination | ||
| 2016-11-07 | Molecular Partners (Switzerland) | resignation |
Resignation | |||
| 2016-11-07 | Neon Therapeutics (USA - MA) | nomination | Cancer - Oncology | Nomination | ||
| 2016-11-04 | Merck KGaA (Germany) | Nantong pharmaceutical plant | opening of new premises |
Cardiovascular diseases - Metabolic diseases - Endocrinological diseases - Hormonal diseases | Opening of new premises | |
| 2016-11-04 | Artes Biotechnology (Germany) BioSun Pharmed (Iran) | HPV (human papilloma virus) vaccine | human papilloma virus infection | development manufacturing production |
Cancer - Oncology - Infectious diseases | Development agreement |
| 2016-11-04 | Nestlé Health Science (Switzerland) Aimmune Therapeutics (USA - CA) | AR101 for peanut allergy | food allergies including peanut allergy | development |
Allergic diseases | Development agreement |
| 2016-11-04 | Advantagene (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-11-03 | Enterome Bioscience (France) | nomination |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Nomination | ||
| 2016-11-03 | Actelion (Switzerland) ReveraGen BioPharma (USA - MD) | vamorolone | Duchenne muscular dystrophy | licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases | Licensing agreement |
| 2016-11-02 | Opexa Therapeutics (USA - TX) | restructuring |
Autoimmune diseases - Neurodegenerative diseases | Restructuring | ||
| 2016-11-02 | Leo Pharma (Denmark) Morphosys (Germany) | monoclonal antibodies | development |
Cancer - Oncology - Dermatological diseases | Development agreement |
